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Abstract
Background: Hyponatremia is a disorder of fluid and electrolyte balance characterized by a
relative excess of body water relative to body sodium content. It is the most common electrolyte
disorder encountered in clinical medicine and is associated with negative outcomes in many chronic
diseases. However, there is limited information in the literature about health care resource use and
costs attributable to the effects of the condition. The purpose of this analysis was to estimate the
annual cost of illness of hyponatremia in the United States.
Methods: The study utilized a prevalence-based cost of illness framework that incorporated data
from publicly available databases, published literature and a consensus panel of expert physicians.
Panel members provided information on: classification of hyponatremia patients, treatment settings
for hyponatremia (i.e., hospital, emergency room, doctor's office), and health care resource use
associated with the diagnosis and treatment of hyponatremia. Low and high prevalence scenarios
were estimated and utilized in a spreadsheet-based cost of illness model. Costs were assigned to
units of resources and summarized across treatment settings.
Results: The prevalence estimate for hyponatremia ranged from 3.2 million to 6.1 million persons
in the U.S. on an annual basis. Approximately 1% of patients were classified as having acute and
symptomatic hyponatremia, 4% acute and asymptomatic, 15%–20% chronic and symptomatic, and
75–80% chronic and asymptomatic. Of patients treated for hyponatremia, 55%–63% are initially
treated as inpatients, 25% are initially treated in the emergency room, and 13%–20% are treated
solely in the office setting. The direct costs of treating hyponatremia in the U.S. on an annual basis
were estimated to range between $1.6 billion and $3.6 billion.
Conclusion: Treatment of hyponatremia represents a significant healthcare burden in the U.S.
Newer therapies that may reduce the burden of hyponatremia in the inpatient setting could
minimize the costs associated with this condition.
Background
Hyponatremia, defined as a serum sodium concentration
([Na+]) less than 135 mEq/L [1], represents a relative
excess of body water relative to body sodium content.
Clinical symptoms are largely related to dysfunction of
the central nervous system, and are more evident when
the decrease in the serum sodium concentration is large or
fast [2]. Although most hyponatremic patients may
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appear to be asymptomatic, severe symptomatic
hyponatremia is a medical emergency that calls for imme-
diate treatment. Complications of severe and rapidly
developing hyponatremia can include seizures, coma,
brain-stem herniation, respiratory arrest, permanent brain
damage, and death [3].
Hyponatremia is the most common electrolyte disorder
encountered in clinical medicine [3]. Incidence rates as
high as 15%–22% have been reported in hospitalized
patients in intensive care units [4] or long-term care facil-
ities [5]. However, most studies have reported a hospital-
based incidence of 1%–4% for more clinically significant
cases of hyponatremia (i.e., serum [Na+] less than 130
mEq/L) [3]. There are no published estimates of the prev-
alence of hyponatremia in the U.S. Miller, Morley, and
Rubenstein [6] reviewed medical charts for 119 nursing
home patients and found that 53% had at least one epi-
sode of hyponatremia over a one-year period. More
recently, Hawkins [7] examined the prevalence of
hyponatremia in 120,137 patients at initial presentation
to healthcare providers in Singapore, and reported a range
from 7.2% in the community care setting to as high as
28.2% for acute care hospitalized patients.
Hyponatremia has also been associated with negative out-
comes in many chronic diseases, most notably in patients
with congestive heart failure [8]. One study of 161
patients with severe congestive heart failure found
hyponatremia to be a significant predictor of cardiovascu-
lar mortality, with 69% of hyponatremic patients dying
within 24 months as compared with 40% of patients
without baseline hyponatremia (P < 0.001) [9]. Results
from a prospective study of 435 hospitalized patients with
congestive heart failure indicated that a serum [Na+] less
than or equal to 135 mEq/L was a significant (P < 0.01)
and independent predictor of major complication or
death during hospitalization; 25% of patients with a
serum [Na+] less than or equal to 135 mEq/L, versus 15%
of those with a serum [Na+] greater than 135 mEq/L expe-
rienced a major complication or died [10]. Similarly, in a
study examining admission hyponatremia among 4,123
geriatric patients, in-hospital mortality was 16% among
patients with admission hyponatremia versus 8% among
those without this condition [11]. And in a general adult
hospitalized population, Anderson et al. [12] found that
mortality rates were 60-fold higher in patients with even
asymptomatic hyponatremia compared to nor-
monatremic patients. The degree to which this strong
association between hyponatremia and negative out-
comes is causally related to the hyponatremia, and might
be improved with more effective therapies, is not known.
There is limited information in the literature about health
care resource use and costs attributable to the effects of
hyponatremia. This may be due to the low incidence of
clinically significant hyponatremia, or due to methodo-
logical challenges of isolating the effects of the condition
since morbidity and mortality are often related to the
underlying medical disorder. Two studies in patients with
congestive heart failure have determined that
hyponatremia is a significant predictor of increased length
of stay[10,13]. To our knowledge, no studies have been
conducted assessing the cost of illness of hyponatremia in
different treatment settings. Such information would be
useful given the likely variation in intensity of resource
use and costs of care associated with hyponatremia.
Against this background, the present study utilized a prev-
alence-based cost-of-illness framework to estimate the
annual cost of illness of hyponatremia in the U.S. The
analysis incorporates data from publicly available data-
bases, published literature, and an expert physician panel.
The resulting cost of illness estimate is presented from the
payor perspective and focuses on direct treatment costs,
while excluding indirect costs (i.e., worker productivity
losses) that may be associated with hyponatremia.
Methods
We used a prevalence-based epidemiologic model to esti-
mate the annual direct costs of hyponatremia in the U.S.
[14]. A differential approach was used; to focus on the
excess burden of hyponatremia, costs related to any diag-
nosis or underlying disease other than hyponatremia were
not taken into account [15]. The two main sources of data
for the analysis were the published literature and an expert
panel. Indirect costs were not included in the analysis as
the expert panel did not feel qualified to assign levels of
work loss or caregiver burden based on the presence of
hyponatremia.
Expert panel
Expert opinion was used in this study because neither the
published literature nor national surveys or databases
contain adequate information on the health care resource
use and costs associated with hyponatremia. The role of
the expert panel was two-fold: first, to provide a classifica-
tion scheme for hyponatremia patients, and second, to
estimate the health care resource use associated with the
diagnosis and treatment of hyponatremia.
Our goal was to choose physicians who are representative
of the types of physicians who encounter hyponatremia in
practice, and are considered experts in the field [16]. An
endocrinologist was chosen as lead physician based on a
review of the published hyponatremia literature. The lead
physician then provided recommendations for other
panel members with an extensive background and experi-
ence in treating patients with hyponatremia. The expert
panel was comprised of six physicians from different spe-Cost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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cialties, including two endocrinologists, one nephrolo-
gist, one cardiologist, one internist, and one intensivist.
A consensus panel was utilized to estimate desired model
parameters for patients with hyponatremia [17]. This
approach was utilized by Murray et al. in their study of the
cost of refractory epilepsy [18], and by Plumb and Guest
in their analysis of the cost of erectile dysfunction in the
UK [19]. A detailed questionnaire was mailed to panel
members in advance of a face-to-face meeting. The panel
members completed the questionnaire prior to the meet-
ing and the responses were summarized and presented to
the panel on the day of the meeting. The questionnaire
results and other issues were then discussed among the
panel members until agreement was reached. Previous
research has found that consensus panel decisions have a
high degree of consistency and validity when compared to
clinical practice [20,21].
The questionnaire covered the following topic areas: clas-
sification of hyponatremia patients, health care resource
use associated with the diagnosis of hyponatremia, initial
treatment settings for hyponatremia, health care resource
use associated with the treatment of hyponatremia, and
the treatment of hyponatremia-related complications.
Classifying hyponatremia patients
The first step in establishing the economic burden of a
given disease or condition is to characterize the patient
population with the condition. The expert panel was
asked to provide a classification scheme for hyponatremic
patients that correlated well with the levels of health care
resource use. For example, if there were two main types of
hyponatremic patients, and one type never used health
care services while the other type had frequent hospitali-
zations, this distinction would be critical for an economic
evaluation. Four classification options were presented to
the panel including: 1) acute [developing within 48
hours] vs. chronic [unknown duration or duration greater
than 48 hours] hyponatremia, 2) symptomatic vs. asymp-
tomatic hyponatremia, 3) a combination of the first two
options (i.e., acute symptomatic, acute asymptomatic,
chronic symptomatic, chronic asymptomatic), or 4) based
on underlying condition (e.g., congestive heart failure,
syndrome of inappropriate antidiuretic hormone secre-
tion [SIADH]). The panel agreed unanimously to base the
economic evaluation on the third option.
The panel was not able to provide a specific percentage
breakdown of hyponatremia patients into the four catego-
ries, but did provide a range of percentages for each cate-
gory. For the purposes of estimating the cost of illness of
hyponatremia, we utilized an approach similar to the one
used by Severens et al in their analysis of the cost of pres-
sure ulcers in the Netherlands whereby the ranges pro-
vided by the expert panel were converted into "low" and
"high" estimates [22] (described in greater detail below).
Estimating prevalence of hyponatremia
The ability to estimate the prevalence of hyponatremia in
the U.S. population was enabled by the availability of two
key data elements. First, publicly available hospital dis-
charge data provided empirical evidence of how many
patients are treated for hyponatremia in an inpatient set-
ting each year in the U.S. The U.S. Government's Health-
care Cost & Utilization Project (HCUP) database contains
hospital discharge data from a 20% sample of U.S. hospi-
tals (approximately 7 million hospital stay records from
1,000 hospitals in 33 states) and yields nationally repre-
sentative estimates of inpatient care [23]. In 2002 there
were an estimated 923,473 hospital stays with either a
principal or secondary discharge diagnosis of
hyponatremia (ICD-9-CM diagnosis code 276.1). We
assumed an average of 1.25 hospital stays per patient,
based on a study by Tierney et al. [24] which reported 954
admissions for the 763 hyponatremic patients in their
sample, to arrive at an estimated 738,778 patients treated
for hyponatremia in an inpatient setting in the U.S.
Second, using the four-level classification system, the
expert panel provided "low" and "high" estimates of the
proportion of hyponatremic patients who are treated; and
"low" and "high" estimates of the proportion initially
treated in an inpatient setting (Table 1). All possible com-
binations of the three sets of low and high estimates in
Table 1 (e.g., one combination would include the "low"
estimate for classification, the "low" estimate for percent-
age treated, and the "low" estimate for percentage treated
as inpatient) were evaluated and resulted in eight separate
estimates of the proportion of all hyponatremic patients
who are treated in an inpatient setting. Based on these cal-
culations, we were able to extrapolate from the number of
"known" hospitalized hyponatremia patients (i.e.
738,778 patients) to produce eight separate estimates of
the total number of persons with hyponatremia in the
U.S.
The following example using the "low" values for each of
the three parameters illustrates our methodology for cal-
culating the prevalence estimate. In this scenario, for every
100,000 individuals with hyponatremia, 1,000 (1%) are
acute and symptomatic. Of those, 900 are treated (90%),
and 585 (65% of those treated) are treated in an inpatient
setting. By adding the 585 acute and symptomatic patients
to the similarly derived values for the acute asymptomatic,
chronic symptomatic, and chronic asymptomatic groups,
we determined there were a total of 13,455 patients
treated for hyponatremia in an inpatient setting for every
100,000 individuals with hyponatremia. Given that an
estimated 738,778 patients were treated in an inpatientCost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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setting in 2002, the total number of individuals with
hyponatremia in the U.S. using this particular combina-
tion of estimates was 5.49 million (738,778 × [100,000/
13,455]).
We repeated this procedure for all eight possible combina-
tions of estimates (e.g. "low", "high", "low"; "high",
"high", low"). The lowest and highest of the eight result-
ing prevalence estimates were then used in subsequent
cost of illness calculations (i.e., "low" scenario and "high"
scenario).
While hyponatremia is defined as a serum sodium con-
centration ([Na+]) less than 135 mEq/L [1], the panel felt
that a serum sodium concentration ([Na+]) less than 130
mEq/L is the threshold for clinically significant
hyponatremia, and therefore the level physicians would
consider the threshold for initiating treatment. Accord-
ingly, the expert panel's estimates of treatment patterns,
and therefore our estimates of prevalence, were based on
a conservative assumption that only patients with clini-
cally significant hyponatremia (serum sodium concentra-
tion ([Na+]) less than 130 mEq/L) are being treated.
Estimating health care resource use
To simplify the costing exercise, the panel first reached
consensus on a mutually exclusive list of initial treatment
settings for patients with hyponatremia, and low and high
estimates for the percentage of patients treated in each set-
ting: inpatient, emergency room (ER) (without being hos-
pitalized), or doctor's office (without being hospitalized
or visiting the emergency room) (Table 2). For those
admitted as an inpatient, the panel estimated the propor-
tion admitted specifically for hyponatremia; and the aver-
age, incremental increase in length of stay due to
hyponatremia for patients admitted due to other condi-
tions. The panel provided detailed information on the
hyponatremia-related tests and procedures that are per-
formed in each treatment setting, and the proportion of
patients receiving each test or procedure. This included
both diagnostic and therapeutic tests and procedures. The
frequency and resource use intensity of follow-up visits
were also estimated by the panel. The panel's estimates of
the proportion of patients receiving each test and proce-
dure performed at the initial evaluation varied depending
on the patient's underlying condition (Table 3). Differ-
ences in the tests and procedures performed were based
on whether the patient's etiology was: 1) SIADH; 2) con-
gestive heart failure, cirrhosis, renal failure, or diuretics; or
3) any other etiology. The panel provided estimates of the
percentage of hyponatremia patients who fell into each of
the three etiological categories. These percentages enabled
us to calculate an absolute number of patients receiving
each test and procedure by underlying condition at initial
evaluation. Estimates of the proportion of patients receiv-
ing each test and procedure performed at follow-up were
based on the initial treatment setting. The number of
patients receiving each test and procedure at initial evalu-
ation and follow-up were multiplied by unit prices to
determine the contribution of tests and procedures to the
total cost of illness.
Table 1: Expert panel estimates used in prevalence calculations
Classification of hyponatremia patients Low High
Acute and symptomatic 1% 1%
Acute and asymptomatic 4% 4%
Chronic and symptomatic 20% 15%
Chronic and asymptomatic 75% 80%
100% 100%
Percent of hyponatremia patients 
treated
Low High
Acute and symptomatic 90% 100%
Acute and asymptomatic 90% 100%
Chronic and symptomatic 66% 85%
Chronic and asymptomatic 10% 20%
Of those treated, percent treated 
initially as inpatient
Low High
Acute and symptomatic 65% 75%
Acute and asymptomatic 65% 75%
Chronic and symptomatic 40% 45%
Chronic and asymptomatic 70% 80%Cost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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Again, the panel provided a range of estimates for many of
the resource use items. Therefore, when calculating the
cost of illness based on the "low" prevalence scenario, we
utilized the low end of the range of resource use estimates
from the expert panel, and vice versa for the "high" prev-
alence scenario. This approach resulted in both the most
conservative and most generous cost of illness estimates.
The questionnaire also addressed neurological complica-
tions due specifically to hyponatremia. However, the
panel agreed that given how infrequently these arise, they
could not provide an accurate estimate of the percentage
of patients who would incur costs for complication-
related resource use. In the rare cases in which a patient
does develop complications, costs are substantial; but
because the number of patients affected is small and could
not be confidently quantified, these costs have not been
included in the analysis.
Cost assignment
The cost of care for patients hospitalized specifically for
hyponatremia was based on the average costs for hospital-
izations with a principal discharge diagnosis of
hyponatremia (ICD-9-CM code 276.1) as determined
from the U.S. Government's Healthcare Cost & Utilization
Project's (HCUP) Nationwide Inpatient Sample (NIS)
2002 database. An average cost-to-charge ratio of 0.53,
estimated based on publicly available Medicare cost
report data [25], was applied to the total billed charges
available in the HCUP; and costs were updated to year
2004 U.S. dollars based on the Consumer Price Index for
hospital inpatient services[26] A daily ("per diem") cost
obtained from a private hospital discharge database was
applied to the incremental days in the hospital due to
hyponatremia for patients with other conditions. Physi-
cian fees associated with office visits, tests, and procedures
were based on national prevailing fees for 2004.[27] Facil-
ity fees were based on Medicare's Ambulatory Payment
Classification (APC) System[28] Unit costs are provided
in Table 4.
Results
Prevalence of hyponatremia in U.S
The prevalence estimates ranged from a low of 3.16 mil-
lion to a high of 6.07 million persons with hyponatremia
in the U.S. on an annual basis. This represents approxi-
mately 1.1%–2.1% of the total U.S. population. We found
the combination that yielded the lowest prevalence esti-
mate to be the one that used the 'low' classification esti-
mates (prevalence distributed as 1% acute and
symptomatic, 4% acute and asymptomatic, 20% chronic
and symptomatic, and 75% chronic and asymptomatic),
the 'high' percentage treated estimates (100% for acute
and symptomatic, 100% for acute and asymptomatic,
85% for chronic and symptomatic, and 20% for chronic
and asymptomatic), and the 'high' percentage treated
inpatient estimates (75% for acute and symptomatic, 75%
for acute and asymptomatic, 45% for chronic and symp-
tomatic, and 80% for chronic and asymptomatic). Using
this combination of estimates, we calculated that 23,400
patients are treated for hyponatremia in an inpatient set-
ting for every 100,000 individuals with hyponatremia.
Based on the 2002 estimated total of 738,778 patients
treated for hyponatremia in an inpatient setting, this
places the overall U.S. prevalence at 3.16 million.
The combination that yielded the highest prevalence esti-
mate was the one that used the 'high' classification esti-
Table 2: Treatment by setting for hyponatremia patients
Inpatient ER Office/Clinic
Low Scenario (3.16 million 
prevalence; 1.17 million 
treated patients)
Overall 63% (738,778) 24% (280,988) 13% (148,387)
Acute and Symptomatic 75% (23,679) 25% (7,893) 0% (0)
Acute and Asymptomatic 75% (94,715) 25% (31,572) 0% (0)
Chronic and Symptomatic 45% (241,524) 45% (241,524) 10% (53,672)
Chronic and Asymptomatic 80% (378,861) 0% (0) 20% (94,715)
High Scenario (6.07 million 
prevalence; 1.35 million 
treated patients)
Overall 55% (738,778) 25% (333,070) 20% (274,036)
Acute and Symptomatic 65% (35,530) 35% (19,131) 0% (0)
Acute and Asymptomatic 65% (106,590) 35% (57,394) 0% (0)
Chronic and Symptomatic 40% (256,544) 40% (256,544) 20% (128,272)
Chronic and Asymptomatic 70% (340,115) 0% (0) 30% (145,764)Cost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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mates (prevalence distributed as 1% acute and
symptomatic, 4% acute and asymptomatic, 15% chronic
and symptomatic, and 80% chronic and asymptomatic),
the 'low' percentage treated estimates (90% for acute and
symptomatic, 90% for acute and asymptomatic, 66% for
chronic and symptomatic, and 10% for chronic and
asymptomatic), and the 'low' percentage treated inpatient
estimates (65% for acute and symptomatic, 65% for acute
and asymptomatic, 40% for chronic and symptomatic,
and 70% for chronic and asymptomatic). Based on this
combination of estimates, 12,164 patients are treated for
hyponatremia in an inpatient setting for every 100,000
individuals with hyponatremia. This places the overall
U.S. prevalence at 6.07 million.
Treatment by setting
Table 2 provides a breakdown of the number and percent-
age of treated hyponatremia patients who receive initial
treatment in each setting of care. Estimates are provided
for both the low and high prevalence scenarios. The expert
panel agreed that a low percentage of patients with
hyponatremia would be treated solely in the office/clinic
setting, and that chronic asymptomatic patients would
not be seen in the ER. Chronic hyponatremia was esti-
mated to account for greater than 80% of patients initially
treated in an inpatient setting, greater than 85% of
patients initially treated in an ER, and generally all
patients initially treated in an office/clinic setting. Overall,
55%–63% of persons with hyponatremia who are treated
are estimated to receive their initial treatment in an inpa-
tient setting, 25% are estimated to be treated initially in
the emergency room, and 13%–20% are treated solely in
the office setting.
There are an estimated 1 million hospitalizations per year
in the U.S. with a principal (accounting for 6.6% of the
stays) or secondary discharge diagnosis of hyponatremia.
Of all patients with hyponatremia in the inpatient setting,
it was estimated that 4%–8% were admitted specifically
for hyponatremia and 58%–67% required a longer length
of stay due to symptomatic hyponatremia, depending
upon the low or high prevalence scenario. The estimate of
the total number of additional days of hospitalization due
to hyponatremia as a comorbid condition ranged from
497,000 to 4.5 million days per year.
Cost of illness
The direct costs of treating hyponatremia in the U.S. on an
annual basis were estimated to range between $1.6 billion
(based on the low prevalence scenario) and $3.6 billion
(using the high prevalence scenario) (Table 5). Hospitali-
zation costs (including readmissions) accounted for
approximately 70% of the total cost of illness. For the
738,778 patients treated in an inpatient setting, hospital-
ization costs were estimated at $1.1 billion, or $1,528 per
patient (low prevalence scenario), to $2.5 billion, or
$3,441 per patient (high prevalence scenario). Hospitali-
zation costs for the subset of patients who were admitted
not specifically for hyponatremia but for another reason
were based strictly on the days their hospital stay was
Table 3: Unit costs
Resource Item Office ER/Inpatient
Professional Fee Professional Fee Facility Fee/Lab Fee
Office and ER Costs
Initial Visit $110.50 $130.77 $157.50
Follow-up visit $71.00 N/A N/A
Chest X-Ray $122.00 $42.57 $55.50
MRI $1,852.50 $388.28 $382.00
Chest CT $1,067.50 $320.68 $352.00
Abdominal CT $923.00 $253.94 $281.50
Urine osmolality $31.00 $31.00 $9.52
TSH $66.00 $66.00 $23.47
ACTH stimulation test $159.50 $159.50 $53.97
Basic metabolic panel $39.50 $39.50 $11.83
Venipuncture $3.00
Inpatient costs
Patients admitted for hyponatremia
Total cost of hospital stay $6,926.00
Patients admitted for another 
condition
Per diem (general ward) $500.00
Per diem (ICU) $1,100.00
Consultation $106.00Cost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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extended due to their hyponatremia. Therefore, the esti-
mated costs for these patients can be attributed solely to
the hyponatremia and are independent of any underlying
comorbid condition that was their primary reason for
admission. Admissions specifically for hyponatremia
accounted for approximately 20% of the hospitalization
costs, with the remaining 80% attributable to patients
admitted for another condition but whose length of stay
was extended due to hyponatremia. Follow-up treatment
was the second largest cost driver, accounting for 15%–
20% of total costs, depending upon the prevalence sce-
nario. In the low prevalence scenario, 577,131 patients
were estimated to require follow-up treatment at a cost of
$263 million, or $456 per patient. In the high prevalence
scenario, the cost for the 754,861 patients requiring fol-
low-up treatment was estimated at $693 million, or $918
per patient.
Discussion
This study indicates that hyponatremia represents a sub-
stantial medical and economic burden in the U.S. There
are approximately 1 million hospitalizations per year in
the U.S. with a principal or secondary discharge diagnosis
of hyponatremia, as well as an estimated 105,000 to
120,000 annual ER visits, and 1.4 million to 3.4 million
annual office visits for hyponatremia. The cost of illness
Table 5: Per patient and total costs of care by treatment setting
Total # of patients $ per patient Total costs
Low Prevalence Scenario
Initial treatment in inpatient setting 738,778 $1,069 $789,604,595
Initial treatment in ER 177,063 $587 $103,950,219
Initial treatment in office setting 148,279 $1,049 $155,513,136
Follow-up treatment 473,097 $453 $214,332,436
Total $ 1,263,400,385
High Prevalence Scenario
Initial treatment in inpatient setting 738,778 $2,721 $2,009,973,806
Initial treatment in ER 234,749 $381 $89,464,969
Initial treatment in office setting 257,305 $1,057 $271,952,427
Follow-up treatment 639,810 $916 $585,770,794
Total $ 2,957,161,995
Table 4: Diagnostic tests and procedures
Chest X-Ray Basic 
Metabolic 
Panel
TSH Urine 
Osmolality
ACTH 
Stimulation 
Test
MRI Chest CT 
with or 
without 
Abdominal 
Scan
Initial Evaluation
Patients with CHF, Cirrhosis, 
Renal Failure, or Taking 
Diuretics
100% 100% 100% 0% 0% 0% 0%
Patients with SIADH 100% 100% 100% 100% 100% 25% 25%
Patients with All Other 
Etiologies
100% 100% 100% 100% 100% 0% 0%
Follow-Up Visits
Initial Treatment in Inpatient 
Setting
100% 100% 0% 0% 0% 0% 0%
Initial Treatment i n  E R  S e t t i n g 1 0 0 % 1 0 0 % 0 %0 % 0 %0 %0 %
Initial Treatment in Office 
Setting
80%–90% 90% 0% 0% 0% 0% 0%Cost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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estimate of $1.6 billion to $3.6 billion for hyponatremia
can be put into perspective by reviewing published direct
cost estimates for other conditions (updated to Year 2004
US $), including $788 million for treating children with
respiratory syncytial virus [29], $1.5 billion for treating
refractory epilepsy in adults [18], $2.3 billion for treating
hay fever [30], $23.4 billion for treating urinary inconti-
nence [31], and $23.7 billion for congestive heart failure
[32].
There have been no previously published estimates of the
total direct costs of treating hyponatremia, but several pre-
vious studies corroborate the conclusions of our analysis.
Results from a prospective study of 435 patients admitted
to a university hospital with evidence of congestive heart
failure showed that hyponatremia (defined as serum
[Na+] less than or equal to 135 mEq/L) was significantly
(P  ≤ 0.01) and independently associated with an
increased duration of hospital stay and higher hospital
cost [10]. The increased length of hospital stay in patients
with hyponatremia was demonstrated in another retro-
spective analysis of 1,046 patients (58% older than 65
years) hospitalized for heart failure [13]. In this study, 171
patients had hyponatremia (defined as serum [Na+] less
than 135 mEq/L) at admission and their mean length of
stay was 5.78 days, versus 4.72 days among patients with-
out hyponatremia (P = 0.0001). The only variable other
than hyponatremia that was associated with a longer
duration of hospitalization in this study was admission
from a skilled nursing facility (6.22 days). A multivariate
linear regression analysis indicated that hyponatremia
was a significant predictor of hospitalization duration in
this cohort of patients.
The current study's cost of illness estimate for
hyponatremia is most likely a conservative one. The prev-
alence estimate was based in large part on the number of
hospitalizations for hyponatremia as recorded (by ICD-9-
CM diagnosis code) in a national database, but there is
evidence that the ICD-9-CM code for hyponatremia repre-
sents only one-third of the patients admitted to the hospi-
tal and experiencing hyponatremia, due to the low
sensitivity (30%) of the diagnosis code [33]. In addition,
a high proportion of hyponatremia in the hospital setting
is iatrogenic [12,34] and hospitals may be reluctant to
include the code in the discharge data.
More definitive resource use and cost data from longitudi-
nal, patient-level databases would have been preferred.
However, as noted above, existing databases have their
own inherent weaknesses due to the lack of sensitivity
with the ICD-9-CM diagnosis code for hyponatremia.
Future studies should therefore consider a broader
national survey of treatment patterns and resource use
associated with hyponatremia.
There are additional limitations associated with this anal-
ysis. Although previous research has found that consensus
panel decisions have a high degree of consistency and
validity when compared with clinical practice [20,21] the
panel estimates in the current study are uncertain. A vari-
ety of formal and informal methods have been developed
for use as consensus-building techniques in group deci-
sion-making [35]. The consensus development process in
this study was a variation of a modified Delphi panel. In
the first stage of a two-stage process, participants privately
completed a mailed questionnaire. In the second stage,
their compiled responses were presented at a face-to-face
meeting where the group engaged in open communica-
tion to discuss any variations in their responses. The panel
members reached consensus as a group on an appropriate
estimate for each question, often in the form of a range.
Unlike a true Delphi panel where participants never meet
directly, a noted strength of the interactive forum is the
opportunity the participants have to provide information,
insight, and rationales for their responses. However, a
limitation of this approach is the potential for decisions to
be reached by persuasion rather than consensus due to an
influential member of the group. While no single member
of the panel in this study appeared to dominate the con-
sensus process, we recognize that social forces such as per-
suasion and conformity may have influenced panel
members' final decisions.
Additional uncertainty in the panel's estimates lay in the
subjective nature of their responses. Previous commentar-
ies in the literature have suggested the potential for bias in
prevalence estimates provided by practicing clinicians
because their experience is based on the duration of ill-
ness, severity, and other clinical characteristics of patients
who receive treatment [36]. For example, the prevalence
of severe and symptomatic hyponatremia may be easier to
estimate than the number of patients who have undetect-
able symptoms. We believe we minimized this potential
bias by having a cross-disciplinary panel familiar with the
variety of ways hyponatremia can present itself (i.e. acute,
chronic, symptomatic, asymptomatic).
Another study limitation is the lack of inclusion of costs
associated with complications of hyponatremia, which
although rare, can be substantial. The panel felt it would
be difficult to quantify the complications for the
extremely small percentage of patients who experience
these events. Resource use and costs associated with com-
plications vary depending on the nature and severity of
the complication. Furthermore, many complications of
hyponatremia are neurological with severe long-term
sequelae. Therefore, an accurate assessment of the eco-
nomic burden would have to include direct and indirect
costs incurred over time, which would vary depending on
several patient, clinical, and treatment factors. Given theCost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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high degree of uncertainty associated with estimating the
economic impact of complications and the low percent-
age of patients involved, the panel deemed it most appro-
priate to exclude complications from the analysis.
The analysis also did not include the indirect costs associ-
ated with hyponatremia. The expert panel did not feel
qualified to assign levels of work loss or caregiver burden
based on the presence of hyponatremia; and there were
no data sources available to directly link hyponatremia
with work loss. The increased mortality risk that has been
linked to hyponatremia [9,10,37] was assumed to apply
mostly to non-working elderly populations, and thus the
productivity losses due to mortality were considered min-
imal.
This analysis of the economic impact of hyponatremia
raises a number of clinical implications that have not
been fully appreciated nor discussed regarding this disor-
der. The clinical importance of symptomatic
hyponatremia has been well appreciated by clinicians
over the past decade, both as a result of the morbidity and
mortality associated with hyponatremic encephalopathy,
as well as that associated from the production of pontine
and extrapontine myelinolysis from overly rapid correc-
tion of severe hyponatremia [38]. However, both of these
situations are relatively rare in terms of overall incidence,
likely representing 1% or less of all hyponatremic patients
(Table 1). While these dramatic cases have appropriately
received much attention in the medical literature, they
represent only a small fraction of the resource utilization
and costs associated with hyponatremia. Rather, the bulk
of the costs attributable to hyponatremia appear to result
from a combination of inpatient hospitalization costs
(70%) and subsequent follow-up evaluation and treat-
ment (15%–20%), and 80% of these are attributable to
those patients for whom hyponatremia was not the pri-
mary diagnosis. Thus, these relatively conservative esti-
mates suggest that more than two-thirds of the cost of
hyponatremia occurs from patients hospitalized for other
conditions whose length of hospital stay is then extended
due to coincident hyponatremia. Further analysis of the
reasons underlying this observation is therefore indicated.
Several possibilities can potentially explain this associa-
tion. First, hyponatremia may be a marker of the severity
of the underlying disease, in which case hospitalizations
are longer simply because the hyponatremic patients rep-
resent a sicker cohort of all those with the underlying dis-
order. Second, hyponatremia may add its own
complications to those of the underlying disorder, thereby
acting as an independent factor that extends the length of
hospital stay due to the intrinsic complications of this dis-
order. Third, the presence of hyponatremia may limit or
otherwise compromise optimal treatment of the underly-
ing disorder. Finally, because newly-discovered
hyponatremia represents a metabolic abnormality of
uncertain etiology and significance, the medical evalua-
tion required to ascertain the underlying cause of the
hyponatremia will necessarily involve investment of addi-
tional time and resources. Each of these possible explana-
tions will be considered in greater detail.
Hyponatremia has long been known to occur in associa-
tion with a variety of underlying conditions, from tumors
that synthesize and excrete arginine vasopressin ectopi-
cally [39] to disorders such as congestive heart failure and
cirrhosis where arginine vasopressin secretion from the
posterior pituitary is stimulated by decreased effective cir-
culating blood volume [40]. It is striking that mortality
rates have been found to be significantly higher in
hyponatremic patients across a broad range of primary
disorders, including congestive heart failure and acute
myocardial infarctions [41], pulmonary tuberculosis [42],
and childhood diarrhea [43]. Perhaps the strongest data
for hyponatremia as a marker of disease severity comes
from multiple studies of patients with congestive heart
failure, which have clearly shown that hyponatremia rep-
resents an independent risk factor in patients with heart
failure [8], nearly doubling the risk of mortality in this
group [44,45]. Most evidence suggests that this associa-
tion reflects the underlying pathophysiology of the heart
failure (i.e., that hyponatremia is a marker of severity of
the underlying disease). This is partly based upon the
findings that arginine vasopressin is one of the hormones
stimulated during the activation of multiple neurohu-
moral systems that occurs in association with progression
of the heart failure. In the SOLVD (Studies of Left Ven-
tricular Dysfunction), subjects with left ventricular dys-
function had significantly higher plasma arginine
vasopressin levels compared to controls, and arginine
vasopressin levels were highest in the subjects with overt
heart failure [46]. While these data support the possibility
that case hospitalizations are longer in hyponatremic
patients because they represent a sicker cohort of all
patients with the underlying disorder, there are a number
of reasons to suggest that the elevated plasma arginine
vasopressin levels associated with hyponatremia may in
fact aggravate disease progression in patients with heart
failure. Specifically, the excess water retention caused by
arginine vasopressin may cause worsening of congestive
heart failure due to diastolic wall stress from the intravas-
cular volume expansion that is caused by the excess
retained water; in addition, the elevated arginine vaso-
pressin levels may lead to increased systolic wall stress as
a result of arteriolar vasoconstriction produced by activa-
tion of vasopressin V1a receptors in the vasculature, and
potential stimulation of myocardial hypertrophy because
of growth-stimulating effects of vasopressin V1a receptors
in the heart. Thus, the assumption that hyponatremia dueCost Effectiveness and Resource Allocation 2006, 4:10 http://www.resource-allocation.com/content/4/1/10
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to increased arginine vasopressin levels is simply a marker
of the severity of the underlying left ventricular dysfunc-
tion in patients with congestive heart failure rather than a
causal factor in the increased mortality of this subgroup
has never been directly tested and remains a presumption.
Regardless of whether elevated arginine vasopressin levels
and hyponatremia directly contribute to the morbidity
and mortality of underlying primary diseases, there is lit-
tle question that the presence of hyponatremia can and
often does interfere with the treatment of underlying dis-
eases through multiple mechanisms. Perhaps most
importantly, standard therapy for euvolemic and hyperv-
olemic patients with hyponatremia is fluid restriction in
order to prevent further water retention and worsening of
the hyponatremia. This necessity can limit therapies that
involve concomitant fluid administration to patients,
including antibiotic therapy, chemotherapy, and
parenteral nutrition. Furthermore, hyponatremic patients
with edema-forming diseases such as congestive heart fail-
ure and cirrhosis who require aggressive diuresis of
retained water and sodium sometimes do not receive as
large a dose of diuretics as otherwise might be given
because of fears of worsening hyponatremia as a result of
the natriuresis produced by conventional diuretic agents.
In each case, this would result in prolonging the period to
reach the medical endpoint of the hospitalization.
Finally, even if none of the above scenarios apply to a spe-
cific case, the current standard of care for newly diagnosed
hyponatremia is to ascertain the etiology of the
hyponatremia before ascribing it to the underlying disease
[47]. This requires a combination of both laboratory and
radiological testing (Table 3) that can add several days to
hospitalization, or alternatively, the employment of these
resources during follow-up visits. In many cases underly-
ing etiologies are not found,[48] raising questions about
the efficacy of the minimum diagnostic evaluation that is
appropriate for all cases of hyponatremia.
While no study to date has definitively ascertained among
the various possible reasons that account for the increased
length of stay in patients with coincident hyponatremia, it
seems likely that all of the factors postulated as potential
causes of increased resource utilization contribute to this
occurrence to varying degrees in individual cases.
Conclusion
In conclusion, approximately 70% of the estimated $1.6
billion to $3.6 billion cost of illness for hyponatremia is
attributable to costs incurred in an inpatient setting. The
majority of these costs are attributable to the incremental
resource utilization for patients who were not admitted
specifically for hyponatremia, but whose hospitalization
was prolonged due to hyponatremia. While the potential
causes for this are multiple and difficult to ascertain with
any degree of certainty, it seems likely that newer thera-
pies that may reduce the incidence and severity of
hyponatremia in the inpatient setting could minimize the
costs of this important clinical disorder.
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